(Reuters) – Sinovac Biotech Ltd said on Tuesday that Indonesian state pharmaceutical manufacturer Bio Farma will produce at least 40 million doses of its potential coronavirus vaccine in the country through March 2021.
The US-listed Chinese pharmaceutical company has signed two agreements with Bio Farma for the supply, production and generation license of its candidate vaccine CoronaVac, and the Indonesian company is conducting the complex candidate-level study.
Sinovac will continue to source the vaccine in bulk until the end of 2021 after March, it said in a statement.
There is no approved vaccine for COVID-19, and drug manufacturers and research organizations are rushing to expand an effective vaccine that is seen as imperative in the fight against the pandemic.
Report via Ankur Banerjee in Bengaluru; Edited via Arun Koyyur
All quotes were delayed for at least 15 minutes. See here for a full list of changes and delays.
© 2020 Reuters. All rights reserved.